Search

Search Constraints

You searched for: Author/Creator Stathis, Anastasios

Search Results

2. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Issue 1 (2nd January 2022)

3. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Issue 11 (27th November 2021)

4. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas. Issue 1 (6th November 2020)

5. A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia. Issue 5 (16th April 2022)

7. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Issue 4 (April 2016)

8. Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. (27th March 2014)

9. Correlation between PSA kinetics and PSMA‐PET in prostate cancer restaging: A meta‐analysis. (11th January 2019)

10. EP294/#883 Elimusertib, an oral ataxia telangiectasia and RAD3-related inhibitor, in advanced gynecologic cancers with DNA damage response defects. (4th December 2022)